Director Shareholding Archives - Advanced Medical Solutions https://admedsol.com/message-type/director-shareholding/ Tue, 21 May 2024 15:03:06 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://admedsol.com/wp-content/uploads/2026/02/cropped-Web-Icon-32x32.png Director Shareholding Archives - Advanced Medical Solutions https://admedsol.com/message-type/director-shareholding/ 32 32 Director/PDMR Shareholding https://admedsol.com/regulatory-news-announcements/director-pdmr-shareholding-22/ Fri, 26 Apr 2024 09:17:24 +0000 https://admedsol1stg.wpenginepowered.com/?post_type=rns-post&p=8373 26 April 2024 Advanced Medical Solutions Group plc (“AMS”, the “Company” or the “Group”)   Director/PDMR Shareholding   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that on 23 April 2024, the Board, following a recommendation from its Remuneration Committee, granted new nil-cost share options to the following Directors/PDMRs under the existing Advanced Medical […]

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]>
26 April 2024

Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that on 23 April 2024, the Board, following a recommendation from its Remuneration Committee, granted new nil-cost share options to the following Directors/PDMRs under the existing Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’). The vesting of these options is based on achieving certain performance criteria for the three years prior to vesting. The performance criteria under the LTIP scheme is split equally between Earnings Per Share (EPS) achievement against target and Total Shareholder Return (TSR) against a comparator group. Directors/PDMRs are required to hold the LTIPs for a period of two years following vesting.

 

Director/PDMR LTIPs prior to grant LTIPs granted Resultant LTIP holdings
Chris Meredith

Chief Executive Officer

 935,567

 

 411,478

 

 1,347,045
Eddie Johnson

Chief Financial Officer

 417,032 169,837

 

 586,869

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Chris Meredith
2. Reason for the notification
a) Position/status: Chief Executive Officer
b) Initial notification/Amendment: Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Advanced Medical Solutions Group plc
b) LEI: 213800HJP6OWOSZI1L74
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594
b) Nature of the transactions:

– Grant of options under the Advanced Medical Solutions Long Term Incentive Plan
c) Price(s) and volume(s):

Sale of shares:

Price(s) Volume(s)
1. – 411,478

 
d) Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a
e) Date of the transaction: 23/04/2024
f) Place of the transaction: Outside of a trading venue

 

 

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Eddie Johnson
2. Reason for the notification
a) Position/status: Chief Financial Officer
b) Initial notification/Amendment: Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Advanced Medical Solutions Group plc
b) LEI: 213800HJP6OWOSZI1L74
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594
b) Nature of the transactions:

– Grant of LTIPs under the Advanced Medical Solutions Long Term Incentive Plan
c) Price(s) and volume(s):

Sale of shares:

Price(s) Volume(s)
1. – 169,837

 
d) Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a
e) Date of the transaction: 23/04/2024
f) Place of the transaction: Outside of a trading venue

 

 

– End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations
ICR Consilium Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Lucy Featherstone AMS@consilium-comms.com
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson
HSBC Bank PLC (Broker) Tel: 44 (0) 20 7991 8888
Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc – see www.admedsol.com

 

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 900 employees. For more information, please see www.admedsol.com.

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]> Director/PDMR and PCA Shareholding https://admedsol.com/regulatory-news-announcements/director-pdmr-and-pca-shareholding-7/ Tue, 02 Apr 2024 14:47:25 +0000 https://admedsol1stg.wpenginepowered.com/?post_type=rns-post&p=8367 02 April 2024 Advanced Medical Solutions Group plc (“AMS”, the “Company” or the “Group”)   Director/PDMR and PCA Shareholding   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 28 March 2024 that on the same day Chris Meredith, who is a Director and PDMR, had sold 40,500 Ordinary Shares […]

The post Director/PDMR and PCA Shareholding appeared first on Advanced Medical Solutions.

]]>
02 April 2024

Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 28 March 2024 that on the same day Chris Meredith, who is a Director and PDMR, had sold 40,500 Ordinary Shares of 5p held on his behalf held in the name of Platform Securities Nominees Limited (“Nominee”), at a price of 196.15p per Ordinary Share.

 

On the same day, the Company was also informed that at the same time Individual Savings Accounts (“ISA’s”) held in the name of Chris Meredith purchased 5,160 Ordinary Shares of 5p, ISA’s held in the name of Ingrid Meredith purchased 3,792 Ordinary Shares of 5p, ISA’s in the name of Chris Meredith’s PCA’s purchased 26,472 Ordinary Shares of 5p and that Lifetime Individual Savings Accounts (“LISA’s”) held in the name of Chris Meredith’s PCA’s purchased 5,076 Ordinary Shares of 5p, all at a price of 196.2p per Ordinary Share.

 

The number of shares, and the beneficial ownership of the shares, held by Chris Meredith, Ingrid Meredith and his PCA’s remains unchanged. These transactions are part of normalised tax planning.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Chris Meredith
2. Reason for the notification
a) Position/status: Director
b) Initial notification/Amendment: Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Advanced Medical Solutions Group plc
b) LEI: 213800HJP6OWOSZI1L74
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594
b) Nature of the transactions:

· Sale of 5,160 Ordinary Shares of 5p held in the name of the Nominee

· Purchase of 5,160 Ordinary Shares of 5p into ISA’s held in the name of Chris Meredith
c) Price(s) and volume(s):

Sale of shares:

Price(s) Volume(s)
Sale of shares from Nominee holding at 196.15p per share 5,160
Purchase by ISA’s at 196.2p per share 5,160

 
d) Aggregated information: (Relates to those shares sold only)

Aggregated volume: 5,160

Aggregated price: 196.15p
e) Date of the transaction: 28/03/2024
f) Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Chris Meredith
2. Reason for the notification
a) Position/status: Director
b) Initial notification/Amendment: Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Advanced Medical Solutions Group plc
b) LEI: 213800HJP6OWOSZI1L74
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594
b) Nature of the transactions:

· Sale of 3,792 Ordinary Shares of 5p held in the name of the Nominee

· Purchase of 3,792 Ordinary Shares of 5p into ISA’s held in the name of Ingrid Meredith
c) Price(s) and volume(s):

Sale of shares:

Price(s) Volume(s)
Sale of shares from Nominee holding at 196.15p per share 3,792
Purchase by ISA’s at 196.2p per share 3,792

 
d) Aggregated information: (Relates to those shares sold only)

Aggregated volume: 3,792

Aggregated price: 196.15p
e) Date of the transaction: 28/03/2024
f) Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Chris Meredith
2. Reason for the notification
a) Position/status: Director
b) Initial notification/Amendment: Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Advanced Medical Solutions Group plc
b) LEI: 213800HJP6OWOSZI1L74
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594
b) Nature of the transactions:

· Sale of 26,472 Ordinary Shares of 5p held in the name of the Nominee

· Purchase of 26,472 Ordinary Shares of 5p into ISA’s held in the name of Chris Meredith’s PCA’s
c) Price(s) and volume(s):

Sale of shares:

Price(s) Volume(s)
Sale of shares from Nominee holding at 196.15p per share 26,472
Purchase by ISA’s at 196.2p per share 26,472

 
d) Aggregated information: (Relates to those shares sold only)

Aggregated volume: 26,472

Aggregated price: 196.15p
e) Date of the transaction: 28/03/2024
f) Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Chris Meredith
2. Reason for the notification
a) Position/status: Director
b) Initial notification/Amendment: Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Advanced Medical Solutions Group plc
b) LEI: 213800HJP6OWOSZI1L74
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594
b) Nature of the transactions:

· Sale of 5,076 Ordinary Shares of 5p held in the name of the Nominee

· Purchase of 5,076 Ordinary Shares of 5p into LISA’s held in the name of Chris Meredith’s PCA’s
c) Price(s) and volume(s):

Sale of shares:

Price(s) Volume(s)
Sale of shares from Nominee holding at 196.15p per share 5,076
Purchase by LISA’s at 196.2p per share 5,076

 
d) Aggregated information: (Relates to those shares sold only)

Aggregated volume: 5,076

Aggregated price: 196.15p
e) Date of the transaction: 28/03/2024
f) Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

– End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations
ICR Consilium Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Lucy Featherstone AMS@consilium-comms.com
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson
HSBC Bank PLC (Broker) Tel: 44 (0) 20 7991 8888
Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc – see www.admedsol.com

 

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 900 employees. For more information, please see www.admedsol.com.

The post Director/PDMR and PCA Shareholding appeared first on Advanced Medical Solutions.

]]> Director/PDMR Shareholding https://admedsol.com/regulatory-news-announcements/director-pdmr-shareholding-21/ Mon, 18 Mar 2024 12:35:42 +0000 https://admedsol1stg.wpenginepowered.com/?post_type=rns-post&p=8365 18 March 2024 Advanced Medical Solutions Group plc (“AMS”, the “Company” or the “Group”)   Director/PDMR Shareholding   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 15 March 2024 that on the same day, Chris Meredith, Director, purchased 23,300 ordinary shares of 5p each (“Ordinary Shares”) at a price of […]

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]>
18 March 2024

Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 15 March 2024 that on the same day, Chris Meredith, Director, purchased 23,300 ordinary shares of 5p each (“Ordinary Shares”) at a price of 191.56p per Ordinary Share and that Eddie Johnson, Director, purchased 27,051 Ordinary Shares of 5p each at a price of 192.20p per Ordinary Share.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: (i) Chris Meredith

(ii) Eddie Johnson
2. Reason for the notification
a) Position/status: (i) Chief Executive Officer

(ii) Chief Financial Officer
b) Initial notification/Amendment: Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Advanced Medical Solutions Group plc
b) LEI: 213800HJP6OWOSZI1L74
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594
b) Nature of the transactions:

· Purchase of Ordinary Shares
c) Price(s) and volume(s):

Price(s) Volume(s)
(i) 191.56p per share 23,300
(ii) 192.20p per share 27,051

 
d) Aggregated information:

N/A
e) Date of the transaction: 15/03/2024
f) Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

– End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations
ICR Consilium Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Lucy Featherstone AMS@consilium-comms.com
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson  

 
HSBC Bank plc (Broker) Tel: 44 (0) 20 7991 8888
Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 900 employees. For more information, please see www.admedsol.com.

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]> Director/PDMR Shareholding https://admedsol.com/regulatory-news-announcements/director-pdmr-shareholding-20/ Mon, 02 Oct 2023 12:46:27 +0000 https://admedsol1stg.wpenginepowered.com/?post_type=rns-post&p=6661 The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]>
RNS Number : 2670O
Advanced Medical Solutions Grp PLC
02 October 2023

Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 28 September 2023 that on the same day, Individual Savings Accounts (“ISA’s”) held in the name of Liz Shanahan, Non-Executive Director, purchased 19,755 ordinary shares of 5p each (“Ordinary Shares”) at a price of 198.64p per Ordinary Share and ISA’s held by Timothy Lacey, husband and a PCA of Liz Shanahan, purchased 30,586 Ordinary Shares at a price of 198.64p per Ordinary Share.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:   (i) Liz Shanahan

            (ii) Timothy Lacey

2.

Reason for the notification

a)

Position/status:             (i) Director

                        (ii) PCA to Liz Shanahan, Non-Executive Director

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·      Purchase of Ordinary Shares

c)

Price(s) and volume(s):

Price(s)

Volume(s)

(i) 198.64p per share

19,755

(ii) 198.64p per share

30,586

d)

Aggregated information:

N/A

e)

Date of the transaction: 28/09/2023

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]> Director/PDMR Shareholding https://admedsol.com/regulatory-news-announcements/director-pdmr-shareholding-19/ Wed, 27 Sep 2023 12:34:46 +0000 https://admedsol1stg.wpenginepowered.com/?post_type=rns-post&p=6648 The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]>
RNS Number : 9007N
Advanced Medical Solutions Grp PLC
27 September 2023

Director/PDMR Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 25 September 2023 that on the same day, Chris Meredith, Director, purchased 23,000 ordinary shares of 5p each (“Ordinary Shares”) at a price of 192.37p per Ordinary Share and that Eddie Johnson, Director, purchased 21,174 Ordinary Shares of 5p each at a price of 193.6p per Ordinary Share.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:   (i) Chris Meredith

            (ii) Eddie Johnson

2.

Reason for the notification

a)

Position/status:             (i) Chief Executive Officer

                        (ii) Chief Financial Officer

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·      Purchase of Ordinary Shares

c)

Price(s) and volume(s):

Price(s)

Volume(s)

(i) 192.37p per share

23,000

(ii) 193.6p per share

21,174

d)

Aggregated information:

N/A

e)

Date of the transaction: 25/09/2023

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

– End –

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]> Director/PDMR Shareholding https://admedsol.com/regulatory-news-announcements/director-pdmr-shareholding-18/ Mon, 22 May 2023 18:13:24 +0000 https://admedsol1stg.wpenginepowered.com/investor-relations/regulatory-news-announcements/no-rid-4924/ RNS Number : 2571A Advanced Medical Solutions Grp PLC 22 May 2023     22 May 2023             Advanced Medical Solutions Group plc (“AMS”, the “Company” or the “Group”)               Director/PDMR Shareholding   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that the Trust which manages […]

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]>

RNS Number : 2571A
Advanced Medical Solutions Grp PLC
22 May 2023
 

 

22 May 2023

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

            Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that the Trust which manages the Share Incentive Plan (“SIP”), previously referred to as the Deferred Share Bonus Plan (“DSB”), on behalf of the employees of AMS has purchased ordinary shares of 5 pence each (“Ordinary Shares”), at a share price of 251.07p on behalf of Chris Meredith and Eddie Johnson, who are both Directors/PDMRs, as part of the SIP and, under the terms of the SIP, these shares will be held in trust on their behalf.

 

Following these transactions the beneficial ownership of Chris Meredith and Eddie Johnson are as follows:

 

Director/PDMR

Date purchased

Shares purchased (through SIP)

Resultant holding

% of issued share capital

Chris Meredith

Chief Executive Officer

18 May 2023

13,859

1,774,021

0.82%

Eddie Johnson

Chief Financial Officer

18 May 2023

19,968

104,277

0.05%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Chief Executive Officer

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of Ordinary Shares as part of the Share Incentive Plan on 18 May 2023

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

251.07p

13,859

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 18/05/2023

f)

Place of the transaction: London Stock Exchange (XLON)

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Eddie Johnson

2.

Reason for the notification

a)

Position/status: Chief Financial Officer

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of Ordinary Shares as part of the Share Incentive Plan on 18 May 2023

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

251.07p

19,968

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 18/05/2023

f)

Place of the transaction: London Stock Exchange (XLON)

 

– Ends –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations



 

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson




HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish


 

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

DSHBRGDUBBDDGXD

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]> Director/PDMR Shareholding https://admedsol.com/regulatory-news-announcements/director-pdmr-shareholding-17/ Tue, 18 Apr 2023 18:22:04 +0000 https://admedsol1stg.wpenginepowered.com/investor-relations/regulatory-news-announcements/no-rid-4908/ RNS Number : 6604W Advanced Medical Solutions Grp PLC 18 April 2023     18 April 2023             Advanced Medical Solutions Group plc (“AMS”, the “Company” or the “Group”)               Director/PDMR Shareholding   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that on 14 April 2023, […]

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]>

RNS Number : 6604W
Advanced Medical Solutions Grp PLC
18 April 2023
 

 

18 April 2023

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

            Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that on 14 April 2023, the Board, following a recommendation from its Remuneration Committee, granted new nil-cost share options to the following Directors/PDMRs under the existing Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’). The vesting of these options is based on achieving certain performance criteria for the three years prior to vesting. The performance criteria under the LTIP scheme is split equally between Earnings Per Share (EPS) growth against fixed targets and Total Shareholder Return (TSR) against a comparator group. The performance criteria have remained unchanged for the last nine years. Directors/PDMRs are required to hold the LTIPs for a period of two years following vesting.

 

Director/PDMR

Options prior to grant

Options granted

Resultant LTIP holdings

Chris Meredith

Chief Executive Officer

733,327

 

324,805

 

1,058,132

Eddie Johnson

Chief Financial Officer

317,696

 

134,063

 

451,759

 

Advanced Medical Solutions Group plc also announces that on 14 April 2023, the Board, following a recommendation from its Remuneration Committee, granted new share options to the following Directors/PDMRs under the Advanced Medical Solutions Deferred Annual Bonus Plan (the ‘2014 DAB’).

 

This award is in respect of the part of their bonus that the Directors/PDMRs are compulsorily required to defer for the 2022 financial year. These options vest at the end of three years. Details of the current DAB holdings of the Directors following these awards are shown below:

 

Director/PDMR

Options prior to grant/exercise

Options granted

Resultant holding

Chris Meredith

Chief Executive Officer

6,219

31,138

37,357

Eddie Johnson

Chief Financial Officer

12,737

13,528

26,265

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Chief Executive Officer

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

1.     Grant of options under the Advanced Medical Solutions Long Term Incentive Plan

2.     Grant of options under the Advanced Medical Solutions Deferred Annual Bonus Plan

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

1. –

324,805

2. –

31,138

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 14/04/2023

f)

Place of the transaction: Outside of a trading venue

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Eddie Johnson

2.

Reason for the notification

a)

Position/status: Chief Financial Officer

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

1.   Grant of options under the Advanced Medical Solutions Long Term Incentive Plan

2.   Grant of options under the Advanced Medical Solutions Deferred Annual Bonus Plan

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

1. –

134,063

2. –

13,528

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 14/04/2023

f)

Place of the transaction: Outside of a trading venue

 

 

– End –

 

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations



 

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson




HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish


 

About Advanced Medical Solutions Group plc – see www.admedsol.com

 

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

DSHBRGDSGDBDGXI

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]> Director/PDMR and PCA Shareholding https://admedsol.com/regulatory-news-announcements/director-pdmr-and-pca-shareholding-6/ Mon, 27 Mar 2023 17:56:40 +0000 https://admedsol1stg.wpenginepowered.com/investor-relations/regulatory-news-announcements/no-rid-4901/ RNS Number : 3734U Advanced Medical Solutions Grp PLC 27 March 2023   27 March 2023 Advanced Medical Solutions Group plc (“AMS”, the “Company” or the “Group”)   Director/PDMR and PCA Shareholding   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 23 […]

The post Director/PDMR and PCA Shareholding appeared first on Advanced Medical Solutions.

]]>

RNS Number : 3734U
Advanced Medical Solutions Grp PLC
27 March 2023
 

27 March 2023

Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 23 March 2023 that on the same day Chris Meredith, who is a Director and PDMR, had sold 35,900 Ordinary Shares of 5p held on his behalf and 8,200 Ordinary Shares of 5p held on behalf of Ingrid Meredith, a PCA of Chris Meredith, both in the name of Platform Securities Nominees Limited (“Nominee”), at a price of 225.5p per Ordinary Share.

 

On the same day, the Company was also informed that at the same time Individual Savings Accounts (“ISA’s”) held in the name of Chris Meredith purchased 8,800 Ordinary Shares of 5p, ISA’s held in the name of Ingrid Meredith purchased 8,200 Ordinary Shares of 5p, ISA’s in the name of Chris Meredith’s PCA’s purchased 22,700 Ordinary Shares of 5p and that Lifetime Individual Savings Accounts (“LISA’s”) held in the name of Chris Meredith’s PCA’s purchased 4,400 Ordinary Shares of 5p, all at a price of 225.6p per Ordinary Share.

 

The number of shares, and the beneficial ownership of the shares, held by Chris Meredith, Ingrid Meredith and his PCA’s remains unchanged. These transactions are part of normalised tax planning.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name: Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument;

(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p



Identification code: GB0004536594

b)

Nature of the transactions:

·       Sale of 8,800 Ordinary Shares of 5p held in the name of the Nominee

·       Purchase of 8,800 Ordinary Shares of 5p into ISA’s held in the name of Chris Meredith

c)

Price(s) and volume(s): Sale of shares:


Price(s)

Volume(s)


Sale of shares from Nominee holding at 225.5p per share

8,800

Purchase by ISA’s at 225.6p per share

8,800

d)

Aggregated information: (Relates to those shares sold only) Aggregated volume: 8,800

Aggregated price: 225.5p

e)

Date of the transaction: 23/03/2023

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name: Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument;

(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594

b)

Nature of the transactions:

·       Sale of 22,700 Ordinary Shares of 5p held in the name of the Nominee



·       Purchase of 22,700 Ordinary Shares of 5p into ISA’s held in the name of Chris Meredith’s PCA’s

c)

Price(s) and volume(s): Sale of shares:


Price(s)

Volume(s)


Sale of shares from Nominee holding at 225.5p per share

22,700

Purchase by ISA’s at 225.6p per share

22,700

d)

Aggregated information: (Relates to those shares sold only) Aggregated volume: 22,700

Aggregated price: 225.5p

e)

Date of the transaction: 23/03/2023

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name: Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument;

(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594

b)

Nature of the transactions:

·       Sale of 4,400 Ordinary Shares of 5p held in the name of the Nominee

·       Purchase of 4,400 Ordinary Shares of 5p into a LISA’s held in the name of Chris Meredith’s PCA’s




c)

Price(s) and volume(s): Sale of shares:


Price(s)

Volume(s)


Sale of shares from Nominee holding at 225.5p per share

4,400

Purchase by LISA’s at 225.6p per share

4,400

d)

Aggregated information: (Relates to those shares sold only) Aggregated volume: 4,400

Aggregated price: 225.5p

e)

Date of the transaction: 23/03/2023

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Ingrid Meredith

2.

Reason for the notification

a)

Position/status: PCA to Chris Meredith, Director

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name: Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument;

(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594

b)

Nature of the transactions:

·       Sale of 8,200 Ordinary Shares of 5p held in the name of the Ingrid Meredith

·       Purchase of 8,200 Ordinary Shares of 5p into ISA’s held in the name of Ingrid Meredith

c)

Price(s) and volume(s): Sale of shares:




Price(s)

Volume(s)


Sale of shares from Nominee holding at 225.5p per share

8,200

Purchase by ISA’s at 225.6p per share

8,200

d)

Aggregated information: (Relates to those shares sold only) Aggregated volume: 8,200

Aggregated price: 225.5p

e)

Date of the transaction: 23/03/2023

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

– End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc                                                 Tel: 44 (0) 1606 545508 Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer Michael King, Investor Relations

 

Consilium Strategic Communications                                                   Tel: 44 (0) 20 3709 5700 Matthew Neal / Lucy Featherstone                                                                                     AMS@consilium-comms.com

 

Investec Bank PLC (NOMAD & Broker)                                                   Tel: 44 (0) 20 7597 5970 Gary Clarence / David Anderson

 

HSBC Bank PLC (Broker)                                                                         Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc – see www.admedsol.com

 

 

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

 

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has


R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

DSHFLFERVSIDFIV

The post Director/PDMR and PCA Shareholding appeared first on Advanced Medical Solutions.

]]> Director/PDMR Shareholding https://admedsol.com/regulatory-news-announcements/director-pdmr-shareholding-16/ Wed, 22 Mar 2023 17:52:17 +0000 https://admedsol1stg.wpenginepowered.com/investor-relations/regulatory-news-announcements/no-rid-4899/ RNS Number : 9237T Advanced Medical Solutions Grp PLC 22 March 2023     22 March 2023             Advanced Medical Solutions Group plc (“AMS”, the “Company” or the “Group”)               Director/PDMR and PCA Shareholding   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was […]

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]>

RNS Number : 9237T
Advanced Medical Solutions Grp PLC
22 March 2023
 

 

22 March 2023

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

            Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 21 March 2023 that on 20 March 2023, a PCA of Liz Shanahan, Non-Executive Director, purchased 2,238 ordinary shares of 5p each (“Ordinary Shares”) at a price of 222.8p per Ordinary Share and 2,206 Ordinary Shares at a price of 226.05p per Ordinary Share.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Timothy Lacey

2.

Reason for the notification

a)

Position/status: PCA to Liz Shanahan, Non-Executive Director

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·      Purchase of Ordinary Shares

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

Purchase of shares at 222.8p per share

2,238

Purchase of shares at 226.05p per share

2,206

d)

Aggregated information:

N/A

e)

Date of the transaction: 20/03/2023

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

– End –

 

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations



 

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

 

 

HSBC Bank plc (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish


 

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see  www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

DSHBRGDXCSDDGXD

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]> Director- PDMR Dealing Announcement https://admedsol.com/regulatory-news-announcements/director-pdmr-dealing-announcement/ Fri, 13 May 2022 18:08:54 +0000 https://admedsol1stg.wpenginepowered.com/investor-relations/regulatory-news-announcements/no-rid-4779/ RNS Number : 5200L Advanced Medical Solutions Grp PLC 13 May 2022     13 May 2022             Advanced Medical Solutions Group plc (“AMS”, the “Company” or the “Group”)               Director/PDMR Shareholding   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces the following PDMR share transactions. […]

The post Director- PDMR Dealing Announcement appeared first on Advanced Medical Solutions.

]]>

RNS Number : 5200L
Advanced Medical Solutions Grp PLC
13 May 2022
 

 

13 May 2022

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

            Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces the following PDMR share transactions.

 

The Company was notified on 10 May 2022 that following his decision to participate in the Deferred Share Bonus (DSB), Chris Meredith, who is a Director and PDMR, undertook the following transactions:

·    The exercise of 395,355 options from the Long-Term Incentive Plan (LTIP).

·    The exercise of 34,608 options from the existing Deferred Annual Bonus Plan (DAB).

·    Elected to receive an additional 543 dividend shares which were earned during the holding period under the terms of the DAB.

·    The exercise of 23,415 Ordinary Shares of 5p from the existing DSB and the award of 56,785 shares under the DSB.

·    The sale of 246,384 Ordinary Shares of 5p each on 10 May 2022 at a share price of 271.5p per Ordinary Share by way of an off-market sale. The proceeds from the sale of the shares was used to purchase shares in the DSB and cover the tax payable on the above exercises.

 

The Trust which manages the Deferred Share Bonus Plan (“DSB”) on behalf of the employees of AMS purchased ordinary shares of 5 pence each (“Ordinary Shares”) between 10 and 12 May 2022, at an average price of 270.5p on behalf of Chris Meredith as part of the DSB and, under the terms of the DSB, these shares will be held in trust on his behalf.

 

As a result of these transactions Chris Meredith’s beneficial interest in the Company increased and his overall holding is as follows:

 

PDMR

No. of DSBs after exercise

No. of DABs after exercise

No. of LTIPs after exercise

Resultant holding of Ordinary Shares

% of issued share capital

Chris Meredith

117,709

6,219

877,145

1,760,162

0.82%

 

The Company was also notified on 12 May 2022 that following the decision by Eddie Johnson, who is a Director and PDMR, to participate in the DSB the Trust which manages the Deferred Share Bonus Plan (“DSB”) on behalf of the employees of AMS purchased ordinary shares of 5 pence each (“Ordinary Shares”)  between 10 and 12 May 2022, at an average price of 270.5p on behalf of Eddie Johnson as part of the DSB and, under the terms of the DSB, these shares will be held in trust on his behalf. Eddie Johnson was awarded of 17,225 shares under the DSB.

 

As a result of these transactions Eddie Johnson’s beneficial interest in the Company increased and his overall holding is as follows:

 

 

PDMR

No. of DSBs after exercise

No. of DABs held

No. of LTIPs held

Resultant holding of Ordinary Shares

% of issued share capital

Eddie Johnson

110,140

12,737

348,258

84,309

0.04%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Exercise of 23,415 shares from the Deferred Share Bonus Plan

·        Exercise of 34,608 shares from the Deferred Annual Bonus Plan

·        Award of 543 Dividend Shares from the Deferred Annual Bonus Plan

·        Exercise of 395,355 shares from the Long-Term Incentive Plan

·        Sale of 246,384 shares

·        Purchase of 28,725 shares through the Deferred Share Bonus Plan

·        Award of 56,785 shares in the Deferred Share Bonus Plan

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

£2.715

246,384

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 246,384

Aggregated price: £2.715

e)

Date of the transaction: 10/05/2022

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Eddie Johnson

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transaction:

·        Purchase of 8,945 shares through the Deferred Share Bonus Plan

·        Award of 17,225 shares in the Deferred Share Bonus Plan

c)

Price(s) and volume(s):

Sale of shares: Nil

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume:

Aggregated price:

e)

Date of the transaction: 10/05/2022

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

-End –

 

 

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer



 

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Matthew Cole

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Gary Clarence




HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish


 

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made three acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

DSHDXLFFLELBBBQ

The post Director- PDMR Dealing Announcement appeared first on Advanced Medical Solutions.

]]>